Status: Not yet recruiting
Ketorolac for Acute Vaso-Occlusive Crisis in Pediatric Sickle Cell Disease
Pediatric patients who present with acute vaso-occlusive pain crisis may have equivalent pain reduction scores at lower dosing of intravenous Ketorolac compared to standard dosing of 0.5 mg/kg/dose IV (\<16yo max 15mg, \>16yo max 30mg) x 1 dose.
Participants needed: 102
Trial details
Phase: Phase 4Age: 1-21Biological sex: AllType: InterventionalSponsor: Children's Blood and Cancer Center at Dell Children's Medical CenterUpdated: Aug 30, 2024
Eligibility criteria
Pediatric patients with sickle cell disease (any genotype) who present to DCMC E...
Patients receiving NSAID medication <6 hours from presentation [+6]